In a recent multi-center study at Departments of Neurosurgery at Charité Universitätsmedizin, Berlin, Technische Universität München and University of California San Francisco(1) outcomes of brain surgery performed because of tumor metastases in the central brain areas were compared between two observational patient cohorts. Cohort 1 included 120 consecutive patients in whom preoperative localization of the motor cortex in relation to the metastasis was performed with Nexstim NBS system. Cohort 2 included 130 consecutive patients in whom NBS motor mapping was not performed because of organizational issues.

Commenting on this positive clinical data, Jarmo Laine, Vice President Medical Affairs stated: “We at Nexstim are excited about the clinical experience of using our technology as part of the care path in these severely afflicted patients. The results reported by the teams at these leading University hospitals are very encouraging”

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim +447715163942

Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com